These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration. Lee JY; Chung H; Kim HC Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799 [TBL] [Abstract][Full Text] [Related]
46. Bevacizumab for neovascular age-related macular degeneration in China. Li X; Hu Y; Sun X; Zhang J; Zhang M; Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896 [TBL] [Abstract][Full Text] [Related]
47. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity. Chang YS; Han JI; Yoo SJ; Lew YJ; Kim JH Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749 [TBL] [Abstract][Full Text] [Related]
48. Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration. Kubicka-Trząska A; Wilańska J; Romanowska-Dixon B; Sanak M Acta Ophthalmol; 2014 Dec; 92(8):e610-4. PubMed ID: 24802549 [TBL] [Abstract][Full Text] [Related]
49. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082 [TBL] [Abstract][Full Text] [Related]
51. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838 [TBL] [Abstract][Full Text] [Related]
52. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255 [TBL] [Abstract][Full Text] [Related]
53. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Murray CD; Wood D; Allgar V; Walters G; Gale RP Eye (Lond); 2014 Oct; 28(10):1218-22. PubMed ID: 25081290 [TBL] [Abstract][Full Text] [Related]
54. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Holz FG; Dugel PU; Weissgerber G; Hamilton R; Silva R; Bandello F; Larsen M; Weichselberger A; Wenzel A; Schmidt A; Escher D; Sararols L; Souied E Ophthalmology; 2016 May; 123(5):1080-9. PubMed ID: 26906165 [TBL] [Abstract][Full Text] [Related]
55. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Berg K; Pedersen TR; Sandvik L; Bragadóttir R Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499 [TBL] [Abstract][Full Text] [Related]